Robison, Heather M.
Chapman, Cole A.
Zhou, Haowen
Erskine, Courtney L.
Theel, Elitza
Peikert, Tobias
Lindestam Arlehamn, Cecilia S.
Sette, Alessandro
Bushell, Colleen
Welge, Michael
Zhu, Ruoqing
Bailey, Ryan C.
Escalante, Patricio
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases at the National Institutes of Health (AI141591, AI141591)
National Center for Advancing Translational Sciences (UL1 TR000135)
Article History
Received: 7 January 2021
Accepted: 21 September 2021
First Online: 15 October 2021
Competing interests
: R.C.B. has a minor financial interest in Genalyte, Inc. P.E. and T.P., and their institution have filed two patent applications related to immunodiagnostic laboratory methodologies for latent tuberculosis infection (Patent numbers: 9678071 and 10401360), which are not included in this manuscript. To date, there has been no income or royalties associated with those filed patent applications. PE participated in a short-term advisory scientific board for DiaSorin Molecular, which was outside the scope of the submitted manuscript, and honorarium was paid to Mayo Clinic. P.E., and T.P. have no other conflicts to declare. H.M.R., C.A.C., H.Z., C.L.E., E.T, C.S.L.A., A.S., C.B., M.W., and R.Z. have no conflicts to declare.